Clinical trials: Chronic Disease Lung
COPD
Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI
The purpose of this study is to determine whether the new inhaler, Bevespi improves lung function. Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, that can provide useful images of the functioning of the…
- Trial name
- COPD (NCT03324607)
- Testing
- hyperpolarized 129Xe gas MRI, Bevespi Aerosphere
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bastiaan Driehuys
Patient Adherence
Efficacy Of An Education Plan And Adherence Follow-Up To The Exercise In Patients With COPD
Chronic obstructive pulmonary disease is one of the main causes of morbidity and mortality worldwide, according to recent publications of the World Health Organization, its main feature is the response to noxious particles of…
- Trial name
- NCT05204498
- Testing
- Education plan and adherence to exercise
- Where
- Colombia
- Volunteers
- 31 people
- Sponsor
- Clínica de Occidente S.A
Renal Insufficiency, Chronic
Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease
Introduction: Currently, chronic kidney disease (CKD) is one of the most serious public health problems, becoming a global epidemic.
- Trial name
- NCT02390193
- Testing
- Hemodialysis
- Where
- Brazil
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Centro Universitário de Anapolis
COPD (Chronic Obstructive Pulmonary Disease), Caregiver
Validation of the French Version of the QASCI in Caregivers of Patients With COPD
This study aims to validate the French version of the QASCI questionnaire, initially written and validated in Portuguese language by Hipolito et al., to assess caregiving burden in chronic obstructive pulmonary disease (COPD).
- Trial name
- VALQASCI (NCT06652204)
- Testing
- questionnaire
- Where
- 2 sites in France
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure)
A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults
Prevora is an antiseptic medication and dental treatment approved by Health Canada for reducing root decay (cavities) in adults at high risk of dental decay. An antiseptic kills germs and harmful bacteria.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure), Dialysis, Chronic Metabolic Disorder
- Trial name
- NCT06158633
- Testing
- Prevora
- Volunteers
- 30 people
- Sponsor
- CHX Technologies Inc.
Dyspnea, Respiratory Insufficiency
Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness in Patients With Advanced Disease
Episodic breathlessness is a common and distressing symptom in patients with advanced disease such as cancer, chronic obstructive pulmonary disease (COPD) and chronic heart failure.
- Conditions
- Dyspnea, Respiratory Insufficiency, Neoplasms, Pulmonary Disease, Chronic Obstructive
- Trial name
- CoBeMEB (NCT04630743)
- Testing
- Cognitive and Behavioral intervention for the Management of Episodic Breathlessness
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- University of Cologne
COPD
Effect of Combined Endurance Training on ADL and Walking in COPD Patients
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease with related exercise intolerance and marked disability due to symptoms such as dyspnea and fatigue.
- Trial name
- NCT05708443
- Testing
- LL group, L+UL group
- Where
- 3 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Hyperphosphatemia, Kidney Disease
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney.
- Trial name
- NCT00660530
- Testing
- Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Illinois Chicago
Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with…
- Conditions
- Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis, Fibrosis, Lung Diseases, Interstitial
- Trial name
- NCT06383819
- Testing
- Longidaza®
- Where
- 30 sites in Russia
- Volunteers
- 392 people
- Sponsor
- NPO Petrovax
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study
Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study.
- Trial name
- NCT02557958
- Testing
- Azithromycin
- Volunteers
- 19 people
- Sponsor
- NYU Langone Health
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
Pulmonary Disease, Chronic Obstructive
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study was to compare the bronchodilator efficacy and safety of ipratropium bromide HFA-134a inhalation aerosol and marketed, Atrovent® CFC Inhalation Aerosol in COPD patients
- Trial name
- NCT02260011
- Testing
- Ipratropium bromide HFA-134a inhalation aerosol, Atrovent® CFC inhalation aerosol
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
COPD Exacerbation
Mast Cells and Its Proteases in COPD
Mast cells proteases such as chymase and tryptase will be studied in the tissue of small and large airways in COPD patients
- Trial name
- NCT06392334
- Testing
- Biopsy
- Where
- Russia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Voronezh N.N. Burdenko State Medical Academy
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
COPD
Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD
This study aims to evaluate how airway inflammation, lung function, and symptoms change over time in people with chronic obstructive pulmonary disease (COPD).
- Trial name
- BREATHE-COPD (NCT07045948)
- Testing
- Blood eosinophil Count
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitair Ziekenhuis Brussel
Chronic Obstructive Pulmonary Disease
COPD Assessment and Management Bundle Versus Usual Care
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory (lung) disease that makes it harder to breathe over time.
- Trial name
- NCT01833026
- Testing
- Spirometry test, Levalbuterol
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Illinois Chicago
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3721 Suspension for Inhalation
To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721…
- Trial name
- NCT05051930
- Testing
- TQC3721 suspension for inhalation
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
Chronic Obstructive Pulmonary Disease
A RESearch on the PrEvalence and the Diagnosis of COPD and Its Tobacco-related Etiology
The aim of the RESPECT study is to gain a better understanding of the prevalence, pathogenesis and symptoms of early chronic obstructive pulmonary disease (COPD).
- Trial name
- RESPECT (NCT02307799)
- Where
- 2 sites in Russia
- Volunteers
- 3,133 people
- Sponsor
- Université Catholique de Louvain
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.